Rhenman & Partners Asset Management AB Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Rhenman & Partners Asset Management AB increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 56.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 145,500 shares of the specialty pharmaceutical company’s stock after buying an additional 52,500 shares during the quarter. Jazz Pharmaceuticals comprises 1.8% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 21st largest position. Rhenman & Partners Asset Management AB’s holdings in Jazz Pharmaceuticals were worth $17,918,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares during the last quarter. GW&K Investment Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 26.6% in the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after buying an additional 97,589 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after acquiring an additional 93,422 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $11,373,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 2,403 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the sale, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock worth $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. HC Wainwright raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $110.04 on Friday. The business’s fifty day moving average is $132.27 and its 200 day moving average is $122.91. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.